CLONIDINE HYDROCHLORIDE EXTENDED-RELEASE- clonidine hydrochloride tablet, extended release

Land: Bandaríkin

Tungumál: enska

Heimild: NLM (National Library of Medicine)

Virkt innihaldsefni:

CLONIDINE HYDROCHLORIDE (UNII: W76I6XXF06) (CLONIDINE - UNII:MN3L5RMN02)

Fáanlegur frá:

American Health Packaging

INN (Alþjóðlegt nafn):

CLONIDINE HYDROCHLORIDE

Samsetning:

CLONIDINE HYDROCHLORIDE 0.1 mg

Stjórnsýsluleið:

ORAL

Gerð lyfseðils:

PRESCRIPTION DRUG

Ábendingar:

Clonidine hydrochloride extended-release tablets are indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications [see CLINICAL STUDIES ( 14)]. Clonidine hydrochloride extended-release tablets are contraindicated in patients with a history of a hypersensitivity reaction to clonidine. Reactions have included generalized rash, urticaria, and angioedema [see ADVERSE REACTIONS ( 6) ] . Pregnancy Category C: Risk Summary There are no adequate or well-controlled studies with clonidine hydrochloride extended-release tablets in pregnant women. In animal embryofetal studies, increased resorptions were seen in rats and mice administered oral clonidine hydrochloride from implantation through organogenesis at 10 and 5 times, respectively, the maximum recommended human dose (MRHD). No embryotoxic or teratogenic effects were seen in rabbits administered oral clonidine hydrochloride during organogenesis at doses up to 3 times the

Vörulýsing:

Clonidine hydrochloride extended-release tablets are available as following: Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. FOR YOUR PROTECTION: Do not use if blister is torn or broken.

Leyfisstaða:

Abbreviated New Drug Application

Vara einkenni

CLONIDINE HYDROCHLORIDE EXTENDED-RELEASE- CLONIDINE HYDROCHLORIDE
TABLET,
EXTENDED RELEASE
AMERICAN HEALTH PACKAGING
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
CLONIDINE HYDROCHLORIDE EXTENDED-
RELEASE TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING
INFORMATION FOR CLONIDINE
HYDROCHLORIDE EXTENDED-RELEASE TABLETS.
CLONIDINE HYDROCHLORIDE EXTENDED-RELEASE TABLETS, FOR ORAL USE
INITIAL U.S. APPROVAL: 1974
INDICATIONS AND USAGE
Clonidine hydrochloride extended-release tablets are a centrally
acting alpha
-adrenergic agonist indicated for the
treatment of attention deficit hyperactivity disorder (ADHD) as
monotherapy or as adjunctive therapy to stimulant
medications. ( 1)
DOSAGE AND ADMINISTRATION
Start with one 0.1 mg tablet at bedtime for one week. Increase daily
dosage in increments of 0.1 mg/day at weekly
intervals until the desired response is achieved. Take twice a day,
with either an equal or higher split dosage being
given at bedtime, as depicted below ( 2.2)
TOTAL DAILY DOSE
MORNING DOSE
BEDTIME DOSE
0.1 mg/day
0.1 mg
0.2 mg/day
0.1 mg
0.1 mg
0.3 mg/day
0.1 mg
0.2 mg
0.4 mg/day
0.2 mg
0.2 mg
Do not crush, chew or break tablet before swallowing. ( 2.1)
Do not substitute for other clonidine products on a mg-per-mg basis,
because of differing pharmacokinetic profiles. (
2.1)
When discontinuing, taper the dose in decrements of no more than 0.1
mg every 3 to 7 days to avoid rebound
hypertension. ( 2.3)
DOSAGE FORMS AND STRENGTHS
Extended-release tablets: 0.1 mg and 0.2 mg, not scored. ( 3)
CONTRAINDICATIONS
History of a hypersensitivity reaction to clonidine. Reactions have
included generalized rash, urticaria, angioedema. ( 4)
WARNINGS AND PRECAUTIONS
Hypotension/bradycardia/syncope: Titrate slowly and monitor vital
signs frequently in patients at risk for hypotension,
heart block, bradycardia, syncope, cardiovascular disease, vascular
disease, cerebrovascular disease or chronic renal
failure. Measure heart rate and blood pressure prior